Pánková Alexandra
Cas Lek Cesk. 2016;155(3):41-3.
Incretine-based therapies are frequently used to treat patients with type 2 diabetes. Some of these drugs are used to induce weight loss. Liraglutide, a glucagon-like peptide 1 receptor agonist, was recently approved for the treatment of obesity. Smoking cessation is associated with weight gain. The mechanism responsible for the increase in body weight post cessation remains unclear. While increased caloric intake may play a role, weight gain may also be linked to nicotine, which has been shown to stimulate smokers basal metabolic rate. The effect of incretines on body weight and energy metabolism after smoking cessation is unclear. Recently published data suggests that incretine hormones may not be involved in the above mentioned changes.
基于肠促胰岛素的疗法常用于治疗2型糖尿病患者。其中一些药物用于诱导体重减轻。利拉鲁肽，一种胰高血糖素样肽1受体激动剂，最近被批准用于治疗肥胖症。戒烟与体重增加有关。戒烟后体重增加的机制尚不清楚。虽然热量摄入增加可能起作用，但体重增加也可能与尼古丁有关，尼古丁已被证明能刺激吸烟者的基础代谢率。肠促胰岛素对戒烟后体重和能量代谢的影响尚不清楚。最近发表的数据表明，肠促胰岛素激素可能不参与上述变化。
